NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...
A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...
Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...
Tuesday, Valneva SE (NASDAQ:VALN) and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease ...
A Pfizer-BioNTech Covid-19 booster shot appears to provide strong protection against the omicron variant, while the initial two-dose vaccine may be insufficient to prevent infection, the companies ...
Pfizer vaccine fails to provide expected immunity for kids ages 2-5 in trials; Extra dose now tested
Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B74710126) describing the safety and immunogenicity of PREVNAR 20™ (Pneumococcal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results